Fecal microbiota transplantation (FMT), a procedure that transfers healthy gut bacteria from a donor to a patient, is emerging as a potential treatment for hepatic encephalopathy, a serious complication of advanced liver disease that impairs brain function. While FMT has generated significant excitement in the medical community, a comprehensive review from Mayo Clinic researchers reveals that the evidence is strong for one specific liver condition but remains preliminary for others .

What Is Hepatic Encephalopathy and Why Does It Matter?

Hepatic encephalopathy (HE) is a neurological condition that develops when a severely damaged liver cannot filter harmful substances from the blood. At its core, HE is a disorder of gut-brain interaction. Ammonia and other bacterial products generated in the gut cross a dysfunctional intestinal barrier, reach a compromised liver, and ultimately impair brain function, causing confusion, memory problems, and in severe cases, loss of consciousness .

This condition primarily affects people with cirrhosis, the most advanced stage of liver disease. For these patients, HE represents a major threat to quality of life and survival, making new treatment options critically important.

How Does FMT Work for Liver Disease?

FMT works by introducing healthy gut bacteria from a donor into a patient's digestive system. For hepatic encephalopathy specifically, the mechanism is elegant and scientifically compelling. The transplanted bacteria accomplish several things simultaneously:

• Reduce ammoniagenic bacteria: The new bacteria reduce the population of bacteria that produce ammonia, one of the primary toxins that damages the brain in HE.
• Increase beneficial bacteria: FMT increases short-chain fatty acid producers like Ruminococcaceae and Bifidobacterium, which support gut health and reduce inflammation.
• Strengthen the gut barrier: The transplanted bacteria tighten the gut epithelial barrier, preventing harmful substances from crossing into the bloodstream.
• Dampen systemic inflammation: By restoring healthy gut bacteria, FMT reduces the widespread inflammation that contributes to brain dysfunction.

This multi-pronged approach directly addresses the root cause of hepatic encephalopathy, which is why researchers are particularly optimistic about FMT for this indication .

What Does the Evidence Actually Show?

The evidence for FMT in hepatic encephalopathy is notably stronger than for other liver diseases. Four randomized or controlled trials in patients with cirrhosis and prior overt HE all showed cognitive improvement signals, meaning patients demonstrated measurable improvements in brain function. Most importantly, the THEMATIC trial demonstrated that FMT recipients were significantly less likely to experience overt HE recurrence than placebo recipients .

However, researchers emphasize an important caveat: we still have not seen a trial powered specifically for clinical outcome detection. This means the studies conducted so far were not large enough to definitively prove that FMT prevents HE episodes in real-world practice, though the signals are encouraging.

"FMT for liver disease is not ready for clinical use outside of a trial. The field needs larger, multisite, well-powered trials with mechanistic sub-studies, standardized oral capsule delivery, and enough patience to wait for 12-month outcomes before claiming victory," stated Patricia Bloom, MD, and colleagues at Mayo Clinic.

Patricia Bloom, MD, Mayo Clinic

What About FMT for Other Liver Diseases?

The picture is far less clear for other liver conditions. Researchers reviewed evidence for FMT in fatty liver disease, alcohol-related liver disease, and primary sclerosing cholangitis, a rare autoimmune liver condition. In each case, the evidence base consists of small, short, largely uncontrolled or underpowered studies .

For metabolic dysfunction-associated fatty liver disease (MAFLD), trials found no effect of FMT on hepatic steatosis (fat accumulation in the liver), insulin resistance, or liver enzyme levels. In alcohol-related liver disease and alcohol use disorder, there is little evidence of benefit that is not driven by biased study design or overestimation of effect from early pilot trials. Until large ongoing trials report results, any claim that FMT treats these conditions should be understood as hypothesis, not conclusion .

How Is FMT Actually Delivered?

One of the most practically important questions in the field is how FMT should be administered. Currently, delivery routes range widely, including colonoscopy, enema, nasogastric tube (through the nose to the stomach), nasoduodenal tube (through the nose to the small intestine), nasojejunal tube (through the nose to another part of the small intestine), and simple oral capsules .

Oral capsules, sometimes informally called "crapsules" by researchers, appear non-inferior to colonoscopy for the best-studied indication, which is recurrent Clostridioides difficile infection. Given that oral capsules are far more scalable, less invasive, and likely more tolerable for chronically ill patients who would need this therapy repeatedly over time, the future almost certainly belongs to encapsulated FMT .

What Questions Remain Unanswered?

Despite the promise of FMT, significant uncertainties remain about how to optimize the therapy. Researchers are still unclear about how efficacy varies with dose, frequency, donor diet, anaerobic versus aerobic bacterial preparation, and whether pooled donors (combining bacteria from multiple donors) work better than single donors. These variables create a complex landscape that may be difficult to resolve through traditional research methods .

The field is moving forward with several large ongoing trials, particularly the PROMISE trial, which will provide crucial data on FMT's effectiveness for alcohol-related liver disease and other conditions. Until these results are published, experts caution against overstating FMT's benefits for liver diseases beyond hepatic encephalopathy.

What Should Patients With Liver Disease Know?

For patients with cirrhosis and hepatic encephalopathy, FMT represents a potentially important new option that addresses the underlying mechanism of their condition. However, it remains primarily available through clinical trials rather than standard medical practice. For patients with other forms of liver disease, FMT should currently be considered experimental, and any use should occur within the context of a research study .

The takeaway is nuanced: FMT is not a miracle cure for all liver diseases, but for one specific condition, hepatic encephalopathy, the evidence is compelling enough to warrant further investigation. As larger, better-designed trials report their results over the coming years, the role of FMT in liver disease treatment will become clearer.